<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02891824</url>
  </required_header>
  <id_info>
    <org_study_id>GINECO-OV236b</org_study_id>
    <nct_id>NCT02891824</nct_id>
  </id_info>
  <brief_title>ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab</brief_title>
  <acronym>ATALANTE</acronym>
  <official_title>A Randomized, Double-blinded, Phase III Study of Atezolizumab Versus Placebo in Patients With Late Relapse of Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated by Platinum-based Chemotherapy and Bevacizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARCAGY/ GINECO GROUP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ARCAGY/ GINECO GROUP</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III, randomized, double-blinded, comparative, multi-centre study to assess&#xD;
      the efficacy of atezolizumab in combination with platinum-based chemotherapy plus bevacizumab&#xD;
      administered concurrent to chemotherapy and in maintenance, in patients presenting epithelial&#xD;
      ovarian cancer (including patients with primary peritoneal and / or fallopian tube&#xD;
      adenocarcinoma) who have platinum-sensitive relapse (platinum-free interval &gt; 6 months).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 600 patients will be randomized using an Interactive Voice Response System&#xD;
      /Interactive web system (IVR/IWR system) in a 1:2 ratio to the treatments as specified below:&#xD;
&#xD;
      A. Arm A: Placebo + bevacizumab &amp; platinum-based chemotherapy.&#xD;
&#xD;
      The placebo arm will include one of 3 following regimens up to investigator choice (chosen&#xD;
      prior to randomization)&#xD;
&#xD;
        1. Carboplatin (day1)combined with gemcitabine (day1 &amp; day8) and bevacizumab (day1) +&#xD;
           placebo ( day1) x 6 cycles q3weeks followed by maintenance with bevacizumab ( day1) +&#xD;
           placebo (day1) q3weeks until disease progression or&#xD;
&#xD;
        2. Carboplatin (d1) combined with paclitaxel (day1) and bevacizumab (day1) + placebo (d1) x&#xD;
           6 cycles every 3weeks followed by maintenance with bevacizumab (day1) + placebo (day1)&#xD;
           q3weeks until disease progression or&#xD;
&#xD;
        3. Carboplatin (day1) combined with pegylated liposomal doxorubicin (PLD) (day1) and&#xD;
           bevacizumab (day1 &amp; 15) + placebo ( day1&amp; 15) x 6 cycles every 4weeks followed by&#xD;
           maintenance with bevacizumab (day1) + placebo (day1) q3weeks until disease progression.&#xD;
&#xD;
      B. Arm B: Atezolizumab + bevacizumab &amp; platinum-based chemotherapy&#xD;
&#xD;
      The atezolizumab arm will include one of 3 following regimens up to investigator choice&#xD;
      (chosen prior to randomization)&#xD;
&#xD;
        1. Carboplatin (day1) combined with gemcitabine (day1 &amp; d8) and bevacizumab (day1) +&#xD;
           atezolizumab ( day1) x 6 cycles q3weeks followed by maintenance with bevacizumab (day1)&#xD;
           + atezolizumab (day1) q3w until disease progression or&#xD;
&#xD;
        2. Carboplatin (day1) combined with paclitaxel (day1) and bevacizumab ( day1) +&#xD;
           atezolizumab (1200mg, d1) x 6 cycles every 3wk (day1) q3weeks until disease progression&#xD;
           or&#xD;
&#xD;
        3. Carboplatin (day1) combined with pegylated liposomal doxorubicin (PLD) (day1) and&#xD;
           bevacizumab (day1 &amp; 15) + atezolizumab (day1&amp; 15) x 6 cycles every 4weeks followed by&#xD;
           maintenance with bevacizumab (day1) + atezolizumab ( day1) q3weeks until disease&#xD;
           progression.&#xD;
&#xD;
      Before randomization to the study:&#xD;
&#xD;
        -  A tumor biopsy should have been obtained and sent to the central laboratory&#xD;
&#xD;
        -  PD-L1 status should be determined&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 22, 2016</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Progression free survival, where the date of progression is based on investigator assessment using the RECIST version 1.1</measure>
    <time_frame>An average of 19 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Overall survival (OS)</measure>
    <time_frame>To be assessed around 73 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Time from date randomization to second subsequent therapy or date of death (TSST) whichever come first</measure>
    <time_frame>To be assessed around 73 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient reported outcome variables</measure>
    <time_frame>to be assessed 19 months</time_frame>
    <description>questionnaire to be completed by patients and collected frequently during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>to be assessed 19 months</time_frame>
    <description>frequency of adverse events according to MedRA terms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">614</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: Placebo + Avastin + platinum-based chemotherapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo arm:&#xD;
Placebo 1200 mg x 6 cycles q3wk or 800mg x 6 cycles q4wk during treatment with chemotherapy and Avastin, followed by placebo 1200mg q3wk until progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Atezolizumab + Avastin+ platinum-based chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The atezolizumab arm:&#xD;
Atezolizumab 1200 mg x 6 cycles q3wk or 800mg x 6 cycles q4wk during treatment with chemotherapy and Avastin, followed by atezolizumab 1200mg q3wk until progression&#xD;
.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atezolizumab + avastin + platinum-based chemotherapy</intervention_name>
    <description>atezolizumab will be administrated by intraveinous route at dose of 1200 mg or 800 mg during the induction period and will be continued in maintenance period at a dose of 1200mg until progression&#xD;
avastin will be administrated by intraveinous route at dose of 15mg/kg or 10 mg/kg during the induction period and will be continued in maintenance period of at a dose of 15mg/kg until progression&#xD;
platinum-based chemotherapy (Carboplatin combined with gemcitabine or paclitaxel or pegylated liposomal doxorubicin) will be administrated by intraveinous route at different doses during the induction period x 6 cycles</description>
    <arm_group_label>Arm B: Atezolizumab + Avastin+ platinum-based chemotherapy</arm_group_label>
    <other_name>Tecentriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo + avastin + platinum-based chemotherapy</intervention_name>
    <description>placebo will be administrated by intraveinous route at dose of 1200 mg or 800 mg during the induction period and will be continued in maintenance period at a dose of 1200mg until progression&#xD;
avastin will be administrated by intraveinous route at dose of 15mg/kg or 10 mg/kg during the induction period and will be continued in maintenance period of at a dose of 15mg/kg until progression&#xD;
platinum-based chemotherapy (Carboplatin combined with gemcitabine or paclitaxel or pegylated liposomal doxorubicin) will be administrated by intraveinous route at different doses during the induction period x 6 cycles</description>
    <arm_group_label>Arm A: Placebo + Avastin + platinum-based chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female Patients must be â‰¥18 years of age.&#xD;
&#xD;
          2. Signed informed consent and ability to comply with treatment and follow-up.&#xD;
&#xD;
          3. Patients with histologically confirmed progressive non-mucinous epithelial ovarian&#xD;
             cancer, primary peritoneal adenocarcinoma and / or fallopian-tube adenocarcinoma&#xD;
&#xD;
          4. Patients with PD-L1 status determined for stratification on mandatory de novo biopsy&#xD;
             sent to central laboratory as a formalin-fixed, paraffin-embedded (FFPE) sample.&#xD;
&#xD;
               -  Cell pellet from pleural effusion, or ascites or lavage are not acceptable.&#xD;
&#xD;
               -  For core needle biopsy specimens, at least three cores should be obtained.&#xD;
                  Biopsies must be obtained in a manner that minimizes risks. If the location of&#xD;
                  the tumor renders tumor biopsy medically unsafe or not feasible, patient&#xD;
                  eligibility should be discussed with the sponsor.&#xD;
&#xD;
          5. Patients whose disease has relapsed more than 6 months from the last dose of platinum&#xD;
             before randomization:&#xD;
&#xD;
               1. criterion for relapse can be according to RECIST v1.1, CA-125 (GCIG) or clinical&#xD;
                  symptoms&#xD;
&#xD;
               2. the interval between last dose of platinum and entry in the study should be free&#xD;
                  of new anti-cancer treatment, with the exception of a maintenance therapy which&#xD;
                  is allowed up to 21 days before study entry.&#xD;
&#xD;
          6. Patients with one or 2 prior lines of chemotherapy. The last line of chemotherapy&#xD;
             should have included platinum.&#xD;
&#xD;
          7. Availability at the study site of representative FFPE tumor sample from surgery during&#xD;
             front line therapy, at best before chemotherapy&#xD;
&#xD;
          8. Patients must have normal organ and bone marrow function :&#xD;
&#xD;
               1. Haemoglobin â‰¥ 10.0 g/dL.&#xD;
&#xD;
               2. Absolute neutrophil count (ANC) â‰¥ 1.5 x 109/L.&#xD;
&#xD;
               3. Platelet count â‰¥ 100 x 109/L.&#xD;
&#xD;
               4. Total bilirubin â‰¤ 1.5 x institutional upper limit of normal (ULN).&#xD;
&#xD;
               5. Aspartate aminotransferase /Serum Glutamic Oxaloacetic Transaminase (ASAT/SGOT))&#xD;
                  and Alanine aminotransferase /Serum Glutamic Pyruvate Transaminase (ALAT/SGPT)) â‰¤&#xD;
                  2.5 x ULN, unless liver metastases are present in which case they must be â‰¤ 5 x&#xD;
                  ULN.&#xD;
&#xD;
               6. Serum creatinine â‰¤ 1.5 x institutional ULN,&#xD;
&#xD;
               7. Patients not receiving anticoagulant medication who have an International&#xD;
                  Normalized Ratio (INR) â‰¤1.5 and an Activated ProThrombin Time (aPTT) â‰¤1.5 x ULN.&#xD;
                  The use of full-dose oral or parenteral anticoagulants is permitted as long as&#xD;
                  the INR or APTT is within therapeutic limits (according to site medical standard)&#xD;
                  and if the patient is on a stable dose of anticoagulants for at least two weeks&#xD;
                  at the time of randomization.&#xD;
&#xD;
               8. Urine dipstick for proteinuria &lt; 2+. If urine dipstick is â‰¥2+, 24-hours urine&#xD;
                  must demonstrate â‰¤1 g of protein in 24 hours.&#xD;
&#xD;
               9. Normal blood pressure or adequately treated and controlled hypertension (systolic&#xD;
                  BP â‰¤ 140 mmHg and/or diastolic BP â‰¤ 90 mmHg).&#xD;
&#xD;
          9. Eastern Cooperative Oncology Group (ECOG) performance status 0-1&#xD;
&#xD;
        For France only: In France, a subject will be eligible for randomization in this study only&#xD;
        if either affiliated to, or a beneficiary of, a social security category&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non-epithelial tumor origin of the ovary, the fallopian tube or the peritoneum (i.e.&#xD;
             germ cell tumors).&#xD;
&#xD;
          2. Ovarian tumors of low malignant potential (e.g. borderline tumors)&#xD;
&#xD;
          3. Patients with synchronous primary endometrial cancer unless both of the following&#xD;
             criteria are met:&#xD;
&#xD;
               1. stage &lt; II,&#xD;
&#xD;
               2. Less than 60 years old at the time of diagnosis of endometrial cancer with stage&#xD;
                  IA or IB grade 1 or 2, or stage IA grade 3 endometrioid adenocarcinoma OR â‰¥ 60&#xD;
                  years old at the time of diagnosis of endometrial cancer with stage IA grade 1or&#xD;
                  2 endometrioid adenocarcinoma.&#xD;
&#xD;
               3. Patients with serous or clear cell adenocarcinoma or carcinosarcoma of the&#xD;
                  endometrium are not eligible.&#xD;
&#xD;
          4. Other malignancy within the last 5 years except cervix or breast in situ carcinoma,&#xD;
             breast cancer â‰¥ 3 years free of disease and treatment, type I stage I endometrial&#xD;
             cancer).&#xD;
&#xD;
          5. Patients receiving radiotherapy within 6 weeks prior to study treatment.&#xD;
&#xD;
          6. Major surgery within 4 weeks of starting study treatment or patients who have not&#xD;
             completely recovered from the effects of any major surgery. Core biopsy or other minor&#xD;
             surgical procedure, excluding placement of a vascular access device, within 7 days&#xD;
             prior to Day 1, Cycle 1&#xD;
&#xD;
          7. Previous allogeneic bone marrow transplant or previous solid organ transplantation.&#xD;
&#xD;
          8. Administration of other simultaneous chemotherapy drugs, any other anticancer therapy&#xD;
             or anti-neoplastic hormonal therapy, or simultaneous radiotherapy during the trial&#xD;
             treatment period (hormonal replacement therapy is permitted).&#xD;
&#xD;
          9. Prior treatment with CD137 agonists or immune checkpoint blockade therapies, anti-PD1,&#xD;
             or anti-PDL1 therapeutic antibodies or anti-CTLA 4.&#xD;
&#xD;
         10. Treatment with systemic immunostimulatory agents (including but not limited to&#xD;
             interferon-alpha (IFN-Î±) and interleukin-2 (IL-2) within 4 weeks or five half-lives of&#xD;
             the drug (whichever is shorter) prior to Cycle 1, Day 1&#xD;
&#xD;
         11. Treatment with systemic corticosteroids or other systemic immunosuppressive&#xD;
             medications (including but not limited to prednisone, dexamethasone, cyclophosphamide,&#xD;
             azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [TNF] agents)&#xD;
             within 2 weeks prior to Cycle 1, Day 1, or anticipated requirement for systemic&#xD;
             immunosuppressive medications during the trial&#xD;
&#xD;
               1. The use of inhaled corticosteroids for chronic obstructive pulmonary disease,&#xD;
                  mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic&#xD;
                  hypotension, and low-dose supplemental corticosteroids for adrenocortical&#xD;
                  insufficiency are allowed.&#xD;
&#xD;
               2. Prophylactic anti-emetic corticosteroids will be avoided if possible in patients&#xD;
                  treated with pegylated liposomal doxorubicin-carboplatin or&#xD;
                  gemcitabine-carboplatin regimen. The use of corticosteroids is allowed as&#xD;
                  premedication for paclitaxel-based regimen and/or premedication in case of&#xD;
                  carboplatin hypersensitivity.&#xD;
&#xD;
         12. History of autoimmune disease, including but not limited to myasthenia gravis,&#xD;
             myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis,&#xD;
             inflammatory bowel disease, vascular thrombosis associated with anti-phospholipid&#xD;
             syndrome, Wegener's granulomatosis, SjÃ¶gren's syndrome, Guillain-BarrÃ© syndrome,&#xD;
             multiple sclerosis, vasculitis, or glomerulonephritis. Are eligible patients with:&#xD;
&#xD;
               1. a history of autoimmune hypothyroidism on a stable dose of thyroid replacement&#xD;
                  hormone&#xD;
&#xD;
               2. controlled Type 1 diabetes mellitus on a stable insulin regimen&#xD;
&#xD;
         13. History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced&#xD;
             pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic&#xD;
             organizing pneumonia), or evidence of active pneumonitis. Radiation pneumonitis in the&#xD;
             radiation field (fibrosis) detected on screening chest CT scan is permitted&#xD;
&#xD;
         14. Immunocompromised patients, e.g., patients who are known to be serologically positive&#xD;
             for human immunodeficiency virus (HIV). Patients with active hepatitis B (defined as&#xD;
             having a positive hepatitis B surface antigen [HBsAg] test at screening) or hepatitis&#xD;
             C.&#xD;
&#xD;
             Patients with past hepatitis B virus (HBV) infection or resolved HBV infection&#xD;
             (defined as having a negative HBsAg test and a positive antibody to hepatitis B core&#xD;
             antigen [anti-HBc] antibody test) are eligible Patients positive for hepatitis C virus&#xD;
             (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for&#xD;
             HCV RNA.&#xD;
&#xD;
         15. Signs or symptoms of infection within 2 weeks prior to Cycle 1, Day 1&#xD;
&#xD;
         16. Administration of a live, attenuated vaccine within 4 weeks prior to Cycle 1, Day 1 or&#xD;
             anticipation that such a live attenuated vaccine will be required during the study.&#xD;
             Influenza vaccination should be given during influenza season only (example&#xD;
             approximately October to March in the Northern Hemisphere). Patients must not receive&#xD;
             live, attenuated influenza&#xD;
&#xD;
         17. Current or recent (within 10 days prior to randomization) chronic use of aspirin &gt; 325&#xD;
             mg/day.&#xD;
&#xD;
         18. Prior history of hypertensive crisis (CTC-AE grade 4) or hypertensive encephalopathy.&#xD;
&#xD;
         19. Inadequately controlled HTN (defined as systolic blood pressure &gt; 150 mmHg and/or&#xD;
             diastolic blood pressure &gt; 100 mmHg on antihypertensive medications)&#xD;
&#xD;
         20. Clinically significant (e.g. active) cardiovascular disease, including:&#xD;
&#xD;
               1. Myocardial infarction or unstable angina within â‰¤ 6 months of randomization,&#xD;
&#xD;
               2. New York Heart Association (NYHA) â‰¥ grade 2 congestive heart failure (CHF),&#xD;
&#xD;
               3. Poorly controlled cardiac arrhythmia despite medication (patients with rate&#xD;
                  controlled atrial fibrillation are eligible),&#xD;
&#xD;
               4. Peripheral vascular disease grade â‰¥ 3 (e.g. symptomatic and interfering with&#xD;
                  activities of daily living [ADL] requiring repair or revision)&#xD;
&#xD;
         21. Resting ECG with QTc &gt; 470 msec on 2 or more time points within a 24 hour period or&#xD;
             family history of long QT syndrome.&#xD;
&#xD;
         22. Left ventricular ejection fraction defined by MUGA/ECHO below the institutional lower&#xD;
             limit of normal (only applicable for patients intended to be treated with pegylated&#xD;
             liposomal doxorubicin).&#xD;
&#xD;
         23. Previous Cerebro-Vascular Accident (CVA), Transient Ischemic Attack (TIA) or&#xD;
             Sub-Arachnoids Hemorrhage (SAH) within 6 months prior to randomization.&#xD;
&#xD;
         24. History or evidence of hemorrhagic disorders within 6 months prior to randomization.&#xD;
&#xD;
         25. Evidence of bleeding diathesis or significant coagulopathy (in the absence of&#xD;
             coagulation).&#xD;
&#xD;
         26. History or clinical suspicion of brain metastases or spinal cord compression. CT/MRI&#xD;
             of the brain is mandatory (within 4 weeks prior to randomization) in case of suspected&#xD;
             brain metastases. Spinal MRI is mandatory (within 4 weeks prior to randomization) in&#xD;
             case of suspected spinal cord compression.&#xD;
&#xD;
         27. History or evidence upon neurological examination of central nervous system (CNS)&#xD;
             disease, unless adequately treated with standard medical therapy (e.g. uncontrolled&#xD;
             seizures).&#xD;
&#xD;
         28. Significant traumatic injury during 4 weeks prior to randomization.&#xD;
&#xD;
         29. Non-healing wound, active ulcer or bone fracture. Patients with granulating incisions&#xD;
             healing by secondary intention with no evidence of facial dehiscence or infection are&#xD;
             eligible but require 3 weekly wound examinations.&#xD;
&#xD;
         30. History of VEGF therapy related abdominal fistula or gastrointestinal perforation.&#xD;
&#xD;
         31. Current, clinically relevant bowel obstruction, including sub-occlusive disease,&#xD;
             related to underlying disease.&#xD;
&#xD;
         32. Patients with evidence of abdominal free air not explained by paracentesis or recent&#xD;
             surgical procedure.&#xD;
&#xD;
         33. Evidence of any other disease, metabolic dysfunction, physical examination finding or&#xD;
             laboratory finding giving reasonable suspicion of a disease or condition that&#xD;
             contraindicates the use of an investigational drug or puts the patient at high risk&#xD;
             for treatment related complications.&#xD;
&#xD;
         34. Women of childbearing potential (&lt;2 years after last menstruation and not surgically&#xD;
             sterile) not willing to use highly-effective means of contraception (Appendix 1)&#xD;
             during the study and for 6 months after the last dose of study medication&#xD;
&#xD;
         35. Pregnant or lactating women.&#xD;
&#xD;
         36. History of severe allergic, anaphylactic, or other hypersensitivity reactions to&#xD;
             chimeric or humanized antibodies or fusion proteins.&#xD;
&#xD;
         37. Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster&#xD;
             ovary cells or to any component of the atezolizumab formulation.&#xD;
&#xD;
         38. Known hypersensitivity reaction or allergy to drugs chemically related to bevacizumab,&#xD;
             carboplatin, gemcitabine, paclitaxel, pegylated liposomal doxorubicin, or their&#xD;
             excipients that contraindicates the subject's participation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Emmanuel KURTZ</last_name>
    <role>Principal Investigator</role>
    <affiliation>GINECO - Institut de cancÃ©rologie Strasbourg Europe</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen BrÃ¼der Graz</name>
      <address>
        <city>Graz</city>
        <zip>8020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uz Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General University Hospital in Prague</name>
      <address>
        <city>Prague</city>
        <zip>128 51</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO Paul Papin</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sainte-Catherine Institut du Cancer Avignon-Provence</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Jean Minjoz</name>
      <address>
        <city>BesanÃ§on</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Tivoli</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut BergoniÃ©</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre FranÃ§ois Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Mutualiste de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Michallon - Centre Hospitalier Universitaire de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier DÃ©partemental Les Oudairies</name>
      <address>
        <city>La Roche sur Yon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre LÃ©on BÃ©rard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital de Mont-de-Marsan</name>
      <address>
        <city>Mont de Marsan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICM Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre AzurÃ©en de CancÃ©rologie</name>
      <address>
        <city>Mougins</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ORACLE - Centre d'Oncologie de Gentilly</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital PrivÃ© du Confluent, S.A.S.</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU NÃ®mes - Institut de CancÃ©rologie du Gard</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier RÃ©gional d'OrlÃ©ans</name>
      <address>
        <city>OrlÃ©ans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Diaconesses-Croix Saint Simon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Saint-Joseph</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital EuropÃ©en Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Hopital Claudius RÃ©gaud</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre BÃ©nite</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre CARIO - HPCA</name>
      <address>
        <city>Plerin Sur Mer</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital de la MilÃ©trie - Centre Hospitalier Universitaire de Poitiers - PÃ´le RÃ©gional de CancÃ©rologie</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre EugÃ¨ne Marquis</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital RenÃ© Huguenin, Institut Curie</name>
      <address>
        <city>Saint-Cloud</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO Centre RenÃ© Gauducheau</name>
      <address>
        <city>Saint-Herblain</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de CancÃ©rologie Strasbourg Europe (ICANS)</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICL Institut de CancÃ©rologie de Lorraine</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CharitÃ©, Campus Virchow-Klinikum, UniversitÃ¤tsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Dusseldorf</name>
      <address>
        <city>Dusseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen Mitte, Evang. Huyssens-Stiftung</name>
      <address>
        <city>Essen</city>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>StÃ¤dtisches Klinikum Karlsruhe</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der UniversitÃ¤t MÃ¼nchen - LMU, Campus GroÃŸhadern</name>
      <address>
        <city>MÃ¼nchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar, Technischen UniversitÃ¤t MÃ¼nchen</name>
      <address>
        <city>MÃ¼nchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sana Klinikum Offenbach</name>
      <address>
        <city>Offenbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Onkologie Ravensburg</name>
      <address>
        <city>Ravensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum TÃ¼bingen</name>
      <address>
        <city>TÃ¼bingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Ulm</name>
      <address>
        <city>ULM</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Worms</name>
      <address>
        <city>Worms</city>
        <zip>67550</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharre Zedek Medical Centre</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital ClÃ­nic Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>8036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de AlcÃ¡ntara</name>
      <address>
        <city>CÃ¡ceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Central Universitario Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar, Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Girona ICO Girona (Dr. Josep Trueta)</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario ClÃ­nico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <zip>7120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Donostia</name>
      <address>
        <city>San SebastiÃ¡n</city>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Alvaro Cunqueiro</name>
      <address>
        <city>Vigo</city>
        <zip>36312</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 25, 2016</study_first_submitted>
  <study_first_submitted_qc>September 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2016</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PD-L1</keyword>
  <keyword>Atezolizumab</keyword>
  <keyword>Randomized, double blinded</keyword>
  <keyword>first or second late relapse</keyword>
  <keyword>progressive non-mucinous epithelial ovarian cancer, primary peritoneal adenocarcinoma and / or fallopian-tube adenocarcinoma</keyword>
  <keyword>progression-free survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

